Study finds siRNA ineffective in reducing mutant huntingtin gene mRNA in nucleus

In Huntington’s disease, the mutant huntingtin gene (HTT) mRNA is retained in the nucleus and forms insoluble clusters. A new study shows that short interfering RNA (siRNA), an oligonucleotide therapeutic strategy that reduces levels of huntingtin mRNA in the cytoplasm, does not lower mutant HTT mRNA expression in the nucleus of mouse brains.

The study is published in the journal Nucleic Acid Therapeutics.

Sarah Allen, from the University of Massachusetts Chan Medical School, and co-authors, state, “Mutant mRNA forms nuclear clusters that are resistant to RNAi, while both nuclear and cytoplasmic wild-type Htt mRNA can be silenced. This study is the first to report on the impact of structure of nuclear RNA impacting efficiency of RNAi-based silencing.”

“Another key investigation from the laboratory of Anastasia Khvorova, to develop our understanding of the relationship between huntingtin RNA and protein levels where it matters functionally,” says Executive Editor Graham C. Parker, Ph.D., Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services